U.S. Medical Foods For Orphan Disease Market Worth $ 527.5 Million By 2030

U.S. Medical Foods For Orphan Disease Market Growth & Trends

The U.S. medical foods for orphan disease market is expected to reach USD 527.5 million by 2030, expanding at a CAGR of 5.6% from 2023 to 2030, based on a new report by Grand View Research, Inc. Increasing healthcare expenditure, awareness about rare diseases, the prevalence of rare diseases, and early screening, are some of the key factors driving the growth of the market. As per the U.S. FDA, phenylketonuria affects about 1 in 15,000 people in the U.S. Similarly, as per the data published by UTAH’s Newborn Screening, tyrosinemia type II affects approximately 1 in 250,000 babies in the U.S.

A unique medical diet is essential for a number of rare disorders in order to prevent severe impairments and promote healthy growth in children and adults. For instance, maple syrup urine disease, food protein-induced enterocolitis syndrome, and short bowel syndrome are some of the common orphan diseases that have specific dietary requirements. Hypoallergenic formulas free of wheat, soy, dairy, and other possible allergens are frequently provided to new-borns and kids with FPIES. These factors continue to be crucial for the expansion.

The COVID-19 pandemic increased the burden on healthcare services and of treatment sensitivity for critically ill patients. Patients who tested positive for COVID-19 typically suffered from weakened immunity and disruption in respiratory & other systems. For instance, according to an article published in Elsevier Public Health Emergency Collection, around half of the critically ill COVID-19 patients developed gastrointestinal problems, such as gastrointestinal hypomotility. Patients experienced various other abdominal issues, which led to increased adoption of medical foods.

The U.S. medical foods for orphan disease market is consolidated, wherein Danone, Abbott, Nestlé, Mead Johnsons, and Relief Therapeutics account for the majority share. These players are adopting several strategies to increase their shares. The development of new products and high R&D investments to develop disease-specific formulas are some of the strategies players implement.

 Request a free sample copy or view report summary: U.S. Medical Foods For Orphan Disease Market Report

U.S. Medical Foods For Orphan Disease Market Report Highlight

• The oral route segment accounted for the highest revenue share in terms of route of administration in 2022 and its revenue share was 70.8%. However, the enteral route is anticipated to grow at the fastest rate over the forecast period

• The powder segment accounted for 35.3% of the revenue share in 2022, the liquid segment is also expected to grow at a lucrative rate over the forecast period

• The others segment accounted for the majority of revenue share in 2022. However, FPIES segment is also expected to grow at a lucrative rate over the forecast period

• Institutional sales held the majority share of 41.1% of the market in terms of sales channel in 2022. However, the online sales segment is expected to grow lucratively over the forecast period

U.S. Medical Foods For Orphan Disease Market Segmentation

Grand View Research has segmented the U.S. medical foods for orphan disease market based on the route of administration, product, application, and sales channel:

U.S. Medical Foods For Orphan Disease Route Of Administration Outlook (USD Million, 2018 - 2030)

• Oral

• Enteral

U.S. Medical Foods For Orphan Disease Product Outlook (USD Million, 2018 - 2030)

• Powder

• Pills

• Liquid

• Others

U.S. Medical Foods For Orphan Disease Application Outlook (USD Million, 2018 - 2030)

• Phenylketonuria

• Tyrosinemia

• Eosinophilic Esophagitis

• FPIES

• MSUD

• Homocystinuria

• Others

U.S. Medical Foods For Orphan Disease Sales Channel Outlook (USD Million, 2018 - 2030)

• Online Sales

• Retail Sales

• Institutional Sales

List of Key Players of U.S. Medical Foods For Orphan Disease Market

• Danone

• Abbott

• Nestlé

• Mead Johnson & Company

• Relief Therapeutics